cfDNA Methylation for Liver Cancer Recurrence Detection
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: plasma GNB4 and Riplet genes methylation detection.
- Who it may be relevant to
- Registry conditions: Primary Liver Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinical Study on the Combined Detection of Plasma GNB4 and Riplet Gene Methylation for Monitoring Primary Liver Cancer Recurrence
Overview
Through follow-up testing of patients with primary liver cancer who underwent hepatectomy, liver transplantation, ablation therapy, or transarterial chemoembolization (TACE), a blinded comparative trial was conducted at each monitoring site. This trial evaluated the combined methylation detection kit for GNB4 and Riplet genes (fluorescent PCR method) against the clinical reference standard (defined as the physician's comprehensive diagnosis based on clinical guidelines and other criteria). The study evaluated the clinical performance of the assay in diagnosing primary liver cancer recurrence and validated the clinical efficacy of methylation detection kits for monitoring recurrence after primary liver cancer treatment.
Interventions
- Diagnostic test plasma GNB4 and Riplet genes methylation detection
Liver cancer patients undergo methylation testing at different follow-up time points after treatment
Primary outcome measures
- sensitivity [Time frame: Through study completion, an average of 1 year]
- specificity [Time frame: Through study completion, an average of 1 year]
Eligibility criteria
Inclusion criteria
- Primary liver cancer
Exclusion criteria
- Concurrent other malignant tumors;
- Ineligible for hepatectomy, liver transplantation, ablation, or TACE therapy;
- Negative methylation status prior to treatment.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan
Identifiers
NCT: NCT07466602 · AD07-2